뇌질환 AI 전문 ‘퍼플에이아이’, 하버드 의대 골드스타인 교수 과학자문위원 영입

Source: beSuccess

Dr. Joshua N. Goldstein – Background

• Professor of Emergency Medicine, Harvard Medical School
• Deputy Chair, Department of Emergency Medicine, Mass General Brigham
• Director, Center for Neurologic Emergencies, Massachusetts General Hospital

Dr. Goldstein is recognized as an authority in neuro‑emergency medicine, leading research on early risk assessment and prognosis for acute stroke and intracerebral hemorrhage.

PurpleAI’s Strategic Plans for the U.S. Market

The advisory agreement is expected to:

• Strengthen clinical credibility for entry into the U.S. market
• Refine study designs to align with U.S. clinical environments
• Enhance data‑validation systems to meet international regulatory standards
• Expand collaborations with major North American healthcare institutions

These steps are intended to incrementally reinforce the core elements required for successful market penetration.

Statement from Dr. Goldstein

“I look forward to collaborating with PurpleAI to reinforce the scientific foundation for early diagnosis and treatment management of stroke and intracerebral hemorrhage patients.”

PurpleAI’s AI Platform and FDA‑Approved Solution

• Building an end‑to‑end AI platform for diagnosis and prognosis of stroke (both hemorrhagic and ischemic) based on its selection as a DeepTech TIPs company by the Ministry of SMEs and Startups in 2025.
• The FDA‑cleared AI solution for intracerebral hemorrhage diagnosis is currently undergoing clinical validation at major U.S. hospitals, including UMass Memorial Health and White Rock Medical Center.

Image credit: PurpleAI